Pay in 4 interest-free payments of $10.00 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
Current Prospects of Molecular Therapeutics in Head and Neck Squamous Cell Carcinoma
Swearingen D
TRPM8 antagonist 2 (0
Dogs receiving capromorelin (30 mg/mL) have food consumption that is significantly greater than dogs treated with placebo
At the opposite
SB-334867 (base) - an orexin antagonist. CAS# 792173-99-0 Catalog No.:M7114-10 Current Prospects of Molecular TherapeuticsSB 334867, an orexin antagonist, CAS No. 792173 99 0, is an orexin antagonist. SB 334867 was the first non peptide antagonist developed that is selective for the orexin receptor subtype OX1, with around 50x selectivity for OX1 over OX2 receptors. It has been shown to produce sedative and anorectic effects in animals, and has been useful in characterising the orexinergic regulation of brain systems involved with appetite and sleep, as well as other
US$ 14.95
US$ 2236.03
US$ 27.93